A new study suggests a cheap and available anti-depressant medication can reduce the risk of severe COVID-19 among those at high risk.

Researchers conducted a trial for the drug that included 1,500 COVID-19 patients in Brazil. Those who took the drug — called fluvoxamine — were less likely to suffer from severe COVID-19 or require hospitalization from the coronavirus, according to CNN.

  • The drug is relatively cheap and available in most locations.
  • It goes by the brand name Luvox.
  • The drug is a selective serotonin reuptake inhibitor (SSRI), which treats obsessive-compulsive disorder and depression, per CNN.
Could Merck’s new COVID-19 pill be a pandemic game changer?
This COVID-19 pill cuts risk of death, hospitalization by 50%
Traffic stop yields drugs and stolen COVID-19 vaccination cards, UHP says

The findings from the study were published in the medical journal The Lancet.

The researchers gave 741 volunteers with a coronavirus infection  fluvoxamine twice a day for 10 days. The other 756 volunteers received a placebo.

  • In total, 79 (so about 11%) of those who got the fluvoxamine needed hospitalization from COVID-19, compared to 16% for those who got the placebo.

Per CNN, the researchers said there will need to be more research to see if the drug will be given to coronavirus patients. The drug costs about $4 for a 10-day supply, which is low compared to antibody treatments, which can cost $2,000, per The Washington Post.

  • “(Fluvoxamine) could be one of our most powerful weapons against the virus,” said study co-author Edward Mills, who works at McMaster University in Ontario, back in August.